Literature DB >> 33008919

Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity.

Pramod C Nair1, Nuy Chau2, Ross A McKinnon2, John O Miners2.   

Abstract

Enzymes of the human UDP-glycosyltransferase (UGT) superfamily typically catalyze the covalent addition of the sugar moiety from a UDP-sugar cofactor to relatively low-molecular weight lipophilic compounds. Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can use both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. An investigation of UGT2B7-catalyzed morphine glycosidation indicated that glucuronidation is the principal route of metabolism because the binding affinity of UDP-GlcUA is higher than that of UDP-Glc. Currently, it is unclear which residues in the UGT2B7 cofactor binding domain are responsible for the preferential binding of UDP-GlcUA. Here, molecular dynamics (MD) simulations were performed together with site-directed mutagenesis and enzyme kinetic studies to identify residues within the UGT2B7 binding site responsible for the selective cofactor binding. MD simulations demonstrated that Arg259, which is located within the N-terminal domain, specifically interacts with UDP-GlcUA, whereby the side chain of Arg259 H-bonds and forms a salt bridge with the carboxylate group of glucuronic acid. Consistent with the MD simulations, substitution of Arg259 with Leu resulted in the loss of morphine, 4-methylumbelliferone, and zidovudine glucuronidation activity, but morphine glucosidation was preserved. SIGNIFICANCE STATEMENT: Despite the importance of uridine diphosphate glycosyltransferase (UGT) enzymes in drug and chemical metabolism, cofactor binding interactions are incompletely understood, as is the molecular basis for preferential glucuronidation by UGT1 and UGT2 family enzymes. The study demonstrated that long timescale molecular dynamics (MD) simulations with a UGT2B7 homology model can be used to identify critical binding interactions of a UGT protein with UDP-sugar cofactors. Further, the data provide a basis for the application of MD simulations to the elucidation of UGT-aglycone interactions.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33008919     DOI: 10.1124/molpharm.120.000104

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

Review 1.  Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs.

Authors:  Pramod C Nair; John O Miners; Ross A McKinnon; Christopher J Langmead; Karen J Gregory; David Copolov; Sherry Kit Wa Chan; Tarun Bastiampillai
Journal:  Mol Psychiatry       Date:  2021-08-10       Impact factor: 15.992

2.  Integrate thermostabilized fusion protein apocytochrome b 562 RIL and N-glycosylation mutations: A novel approach to heterologous expression of human UDP-glucuronosyltransferase (UGT) 2B7.

Authors:  Jia Xue; Haitao Zhang; Su Zeng
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

3.  Genome-wide identification, characterization, and expression analysis of UDP-glycosyltransferase genes associated with secondary metabolism in alfalfa (Medicago sativa L.).

Authors:  Andong Yu; Xueqian Jiang; Yan Sun; Qiannan Hu; Xiaoxi Zhu; Junmei Kang; Lin Chen; Lin Liu; Linfeng Hao; Qingchuan Yang; Ruicai Long; Mingna Li
Journal:  Front Plant Sci       Date:  2022-09-30       Impact factor: 6.627

4.  A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation.

Authors:  Shannon Robin; Khalil Ben Hassine; Tiago Nava; Chakradhara Rao S Uppugunduri; Marc Ansari; Jayaraman Muthukumaran; Simona Jurkovic Mlakar; Maja Krajinovic
Journal:  BMC Mol Cell Biol       Date:  2022-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.